Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;4(2):177-81.
doi: 10.1007/s12265-010-9253-z. Epub 2010 Dec 23.

Cell therapy for cardiovascular disease: a comparison of methods of delivery

Nabil Dib  1 , Harris Khawaja, Samantha Varner, Megan McCarthy, Ann Campbell
Affiliations
Review

Cell therapy for cardiovascular disease: a comparison of methods of delivery

Nabil Dib et al. J Cardiovasc Transl Res. 2011 Apr.

Abstract

The field of myocardial regeneration utilizing novel cell-based therapies, gene transfer, and growth factors may prove to play an important role in the future management of ischemic heart disease and cardiomyopathy. Phases I and II clinical trials have been published for a variety of biologics utilizing four methods of delivery: systemic infusion, intracoronary infusion, transvenous coronary sinus, and intramyocardial. This review discusses the advantages and disadvantages of the delivery approaches above.

PubMed Disclaimer

References

    1. American Heart Association Heart Disease and Stroke Statistics . Update at-a-glance. Dallas: American Heart Association; 2010.
    1. Dib N, Menasche P, Bartunek J, et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. Journal of the American College of Cardiology Cardiovascular Interventions. 2010;3:265–275. - PubMed
    1. Hou D, Youssef EA, Brinton TJ, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation. 2005;112(Suppl I):I150–I156. - PubMed
    1. Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T. Catheter-based delivery of cells to the heart. Nature Clinical Practice. Cardiovascular Medicine. 2006;3(Suppl 1):S58–S60. - PubMed
    1. Biocardia (2005) A Phase I/II, Randomized, double-blinded, placebo-controlled study of the safety and efficacy of transendocardial injection of autologous human cells (bone marrow or mesenchymal) in patients with chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction. http://clinicaltrials.gov/archive/NCT00102128/2005_12_08. Accessed 9 February 2010. - PubMed

MeSH terms

LinkOut - more resources